“All of our locations and expansions are driven by the clinical trial requests from biotech and pharma sponsors that we work with,” Kayt Leonard a PSI CRO spokesperson told Outsourcing-Pharma.com.
Additionally, she said the contract research organization’s (CRO) sites in Spain have demonstrated “a consistent and reliable data delivery.” Specifically, in the areas of oncology and oncohematology.
Leonard also noted that being in the capital city provides the company with access to various resources.
Moving into 2018, Leonard said PSI will continue to grow, though “plans and locations are all based on where our clients need us to be, combined with where we can best contribute to clinical trials.”
“We’ve grown organically for the past 22 years, and we’ll continue in that manner throughout 2018 and beyond,” she added.
In September, PSI announced a string of investments in the Asia Pacific region, with a new office in Seoul, South Korea, as well as Taipei, Taiwan.